Recent Updates — RZLT

Rezolute, Inc. reported financial results for the fourth quarter and full fiscal year ended June 30, 2026. Cash, cash equivalents, and investments totaled $107.8 million as of June 30, 2026. Full-year research and development expenses were $53.8 million, while general and administrative expenses rose to $29.2 million due to increased stock-based compensation and professional fees. The company reported a full-year net loss of $77.6 million compared to $74.4 million in fiscal 2025. Clinically, the Phase 3 upLIFT study for tumor hyperinsulinism is ongoing with topline results expected before year-end 2026, while the sunRIZE study data for congenital HI remains under FDA review following a primary endpoint miss. Rezolute operates in the biotechnology industry, developing ersodetug as an investigational therapy for refractory hypoglycemia caused by hyperinsulinism.